Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
03
2022
revised:
29
03
2022
accepted:
23
05
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
9
7
2022
Statut:
epublish
Résumé
Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis are associated with poor clinical outcomes. A total of 143 COPD patients with chronic bronchitis were screened, and as a result, only 100 patients were enrolled in this study (50 participants were randomized to receive placebo, and others were randomized to receive NAC). After treatment, differences in SGQR scores between the placebo and NAC groups were not significant. Moreover, differences in secondary end points between the two groups after treatment were insignificant.
Sections du résumé
Background
UNASSIGNED
Patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis are associated with poor clinical outcomes.
Results
UNASSIGNED
A total of 143 COPD patients with chronic bronchitis were screened, and as a result, only 100 patients were enrolled in this study (50 participants were randomized to receive placebo, and others were randomized to receive NAC). After treatment, differences in SGQR scores between the placebo and NAC groups were not significant. Moreover, differences in secondary end points between the two groups after treatment were insignificant.
Identifiants
pubmed: 35795313
doi: 10.1155/2022/9133777
pmc: PMC9251103
doi:
Substances chimiques
Acetylcysteine
WYQ7N0BPYC
Types de publication
Journal Article
Randomized Controlled Trial
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
9133777Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2022 Li Zhang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
COPD. 2005 Jun;2(2):209-16
pubmed: 17136947
JAMA. 1989 Aug 18;262(7):925-30
pubmed: 2754793
Expert Opin Pharmacother. 2009 Mar;10(4):719-22
pubmed: 19284368
Int J Chron Obstruct Pulmon Dis. 2018 May 10;13:1507-1514
pubmed: 29785100
Eur J Clin Invest. 2000 Oct;30(10):915-29
pubmed: 11029607
COPD. 2006 Dec;3(4):195-202
pubmed: 17361500
J Appl Physiol (1985). 1987 Jul;63(1):152-7
pubmed: 3040659
Eur Respir J. 2000 Feb;15(2):285-90
pubmed: 10706493
Lancet Respir Med. 2014 Mar;2(3):187-94
pubmed: 24621680
Lancet. 2005 Apr 30-May 6;365(9470):1552-60
pubmed: 15866309
Eur Respir J. 2000 Aug;16(2):253-62
pubmed: 10968500
N Engl J Med. 2007 Feb 22;356(8):775-89
pubmed: 17314337
Am J Respir Crit Care Med. 2013 Feb 1;187(3):228-37
pubmed: 23204254
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Ann N Y Acad Sci. 1963 Mar 30;106:298-310
pubmed: 13977050
Trends Pharmacol Sci. 2002 Aug;23(8):360-6
pubmed: 12377577